Top

Published in:

Open Access 01-12-2013 | Research

MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117⁺CD44⁺ ovarian cancer stem cells by regulating epithelial-mesenchymal transition

Authors: Dengyu Chen, Yunxia Zhang, Jing Wang, Junsong Chen, Cuiping Yang, Kai Cai, Xiaoying Wang, Fangfang Shi, Jun Dou

Published in: Journal of Ovarian Research | Issue 1/2013

Abstract

Background

Cancer stem cells (CSCs) are believed to be ‘seed cell’ in cancer recurrence and metastasis. MicroRNAs (miRNAs) can play an important role in the progression of primary tumor towards metastasis by regulating the epithelial-mesenchymal transition (EMT). The goal of this study was to investigate the effect of miRNA-200c overexpression on the EMT, tumorigenicity and metastasis of epithelial ovarian cancer (EOC) CSCs.

Methods

The EOC CD117⁺CD44⁺CSCs were isolated from the human ovarian cancer cell line SKOV3 by using a magnetic-activated cell sorting system, and the lentivirus miR-200c transduced CSCs were then selected for the study. The assays of colony forming, wound healing, cellular migration in vitro and tumor progression in vivo were performed.

Results

The miR-200c expression was reduced in the CD117⁺CD44⁺CSCs compared with the non-CD117⁺CD44⁺CSCs. However, the stable overexpression of the miR-200c in the CD117⁺CD44⁺CSCs resulted in a significant down-regulation of ZEB-1 and the Vimentin expression, an upregulation of the E-cadherin expression as well as a decrease of colony forming, migratory and invasion in vitro. Importantly, the miR-200c overexpression significantly inhibited the CD117⁺CD44⁺CSCs xenograft growth and lung metastasis in vivo in nude mice by inhibition of the EMT. In addition, the down-regulation of ZEB-1 showed the same efficacy as the miR-200c overexpression in the CD117⁺CD44⁺CSCs.

Conclusion

These findings from this study suggest that the miR-200c overexpression may be considered a critical approach for the EOC CD117⁺CD44⁺CSCs in clinical trials.

Available only for authorised users

Bendoraite A, Knouf EC, Garg KS: Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010, 116: 117–125. 10.1016/j.ygyno.2009.08.009PubMedCentralPubMedCrossRef

Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M: Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011, 12: 273–285. 10.1016/S1470-2045(11)70012-2PubMedCrossRef

Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC: Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res 2012, 5: 44. 10.1186/1757-2215-5-44PubMedCentralPubMedCrossRef

Korbut E, Ptak-Belowska A, Brzozowski T: Mechanisms promoting physiological cells progression into tumorigenesis. J Physiol Pharmacol 2012, 63: 565–570.PubMed

Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA: Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein- related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One 2013, 8: e57056. 10.1371/journal.pone.0057056PubMedCentralPubMedCrossRef

Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, Silasi DA, Rutherford T, Mor G: Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2013, 32: 39–49. 10.1038/onc.2012.33PubMedCentralPubMedCrossRef

Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK: Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther 2012, 11: 2556–2565. 10.1158/1535-7163.MCT-12-0463PubMedCentralPubMedCrossRef

Bracken CP, Gregory PA, Kolesnikoff N: A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial- mesenchymal transition. Cancer Res 2008, 68: 7846–7854. 10.1158/0008-5472.CAN-08-1942PubMedCrossRef

He X, Wang J, Zhao F, Yu F, Chen D, Cai K, Yang C, Chen J, Dou J: Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse. Immunol Res 2012, 52: 240–249. 10.1007/s12026-012-8332-4PubMedCrossRef

10.

Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14: 2690–2695. 10.1158/1078-0432.CCR-07-1731PubMedCrossRef

11.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial- mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133: 704–715. 10.1016/j.cell.2008.03.027PubMedCentralPubMedCrossRef

12.

Berry NB, Bapat SA: Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovarian Res 2008, 1: 8. 10.1186/1757-2215-1-8PubMedCentralPubMedCrossRef

13.

Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28: 209–218. 10.1038/onc.2008.374PubMedCrossRef

14.

Ho CM, Chang SF, Hsiao CC, Chien TY, Shih DT: Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. J Biomed Sci 2012, 19: 23. 10.1186/1423-0127-19-23PubMedCentralPubMedCrossRef

15.

Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68: 4311–4320. 10.1158/0008-5472.CAN-08-0364PubMedCentralPubMedCrossRef

16.

Chen J, Wang J, Chen D, Yang J, Yang C, Zhang Y, Zhang H, Dou J: Evaluation of characteristics of CD44⁺ CD117⁺ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol 2013, 14: 7. 10.1186/1471-2121-14-7PubMedCentralPubMedCrossRef

17.

Dou J, Pan M, Wen P, Li Y, Tang Q, Chu L, Zhao F, Jiang C, Hu W, Hu K, Gu N: Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 2007, 4: 467–472.PubMed

18.

Choi YP, Shim HS, Gao MQ, Kang S, Cho NH: Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett 2011, 307: 62–71. 10.1016/j.canlet.2011.03.018PubMedCrossRef

19.

Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M: Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011, 71: 6320–6326. 10.1158/0008-5472.CAN-11-1021PubMedCrossRef

20.

Liu SJ, Tetzlaff MT, Cui R, Xu X: miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1. Am J Pathol 2012, 181: 1823–1835. 10.1016/j.ajpath.2012.07.009PubMedCentralPubMedCrossRef

21.

Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9: 582–589. 10.1038/embor.2008.74PubMedCentralPubMedCrossRef

22.

Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, He X, Li X, Zou D, Gu N: Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int 2011, 35: 227–234. 10.1042/CBI20100347PubMedCrossRef

23.

Dou J, Li Y, Zhao F, Hu W, Wen P, Tang Q, Chu L, Wang Y, Cao M, Jiang C, Gu N: Identification of tumor stem-like cells in a mouse myeloma cell line. Cell Mol Biol (Noisy-le-Grand) 2009,55(Suppl):OL1151-OL1160.

24.

Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ: Characterization of clonogenic multiple myeloma cells. Blood 2004, 103: 2332–2336. 10.1182/blood-2003-09-3064PubMedCentralPubMedCrossRef

25.

Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J: PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer 2012, 106: 1486–1494. 10.1038/bjc.2012.130PubMedCentralPubMedCrossRef

26.

Ngora H, Galli UM, Miyazaki K, Zöller M: Membrane-bound and exosomal metastasis- associated C4.4A promotes migration by associating with the α(6)β(4) integrin and MT1-MMP. Neoplasia 2012, 14: 95–107.PubMedCentralPubMedCrossRef

27.

Dou J, Liu P, Zhang X: Cellular response to gene expression profiles of different hepatitis C virus core protein in Huh-7 cell line with microarray analysis. J Nanosci Nanotechnol 2005, 5: 1230–1235. 10.1166/jnn.2005.209PubMedCrossRef

28.

Hu W, Wang J, Dou J, He X, Zhao F, Jiang C, Yu F, Hu K, Chu L, Li X, Gu N: Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplant 2011, 20: 669–680. 10.3727/096368910X536509PubMedCrossRef

29.

Yu F, Wang J, Dou J, Yang H, He X, Xu W, Zhang Y, Hu K, Gu N: Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine 2012, 8: 1337–1344. 10.1016/j.nano.2012.02.015PubMedCrossRef

30.

Hu K, He X, Yu F, Yuan X, Hu W, Liu C, Zhao F, Dou J: Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis. Immunol Invest 2011, 40: 265–278. 10.3109/08820139.2010.534219PubMedCrossRef

31.

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM: MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67: 8699–8707. 10.1158/0008-5472.CAN-07-1936PubMedCrossRef

32.

Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, Zhang Y, Wood W III, Becker KG, Morin PJ: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008, 3: e2436. 10.1371/journal.pone.0002436PubMedCentralPubMedCrossRef

33.

Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 2011, 121: 200–205. 10.1016/j.ygyno.2010.12.339PubMedCrossRef

34.

Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Bützow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008, 105: 7004–7009. 10.1073/pnas.0801615105PubMedCentralPubMedCrossRef

35.

Kurman RJ, Shih IM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34: 433–443. 10.1097/PAS.0b013e3181cf3d79PubMedCentralPubMedCrossRef

36.

Lengyel E: Ovarian cancer development and metastasis. Am J Pathol 2010, 177: 1053–1064. 10.2353/ajpath.2010.100105PubMedCentralPubMedCrossRef

37.

Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, Zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009, 12: 1487–1495.CrossRef

Title: MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition
Authors: Dengyu Chen
Yunxia Zhang
Jing Wang
Junsong Chen
Cuiping Yang
Kai Cai
Xiaoying Wang
Fangfang Shi
Jun Dou
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2013
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-6-50

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117⁺CD44⁺ ovarian cancer stem cells by regulating epithelial-mesenchymal transition

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Establishment and characterization of a cell line (NOMH-1) originating from a human endometrioid adenocarcinoma of the ovary

No evidence for PALB2 methylation in high-grade serous ovarian cancer

Regulation of angiotensin II type 1 receptor expression in ovarian cancer: a potential role for BRCA1

Benign and malignant ovarian steroid cell tumors, not otherwise specified: case studies, comparison, and review of the literature

RETRACTED ARTICLE: Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis

The effect of calorie restriction on the presence of apoptotic ovarian cells in normal wild type mice and low-plasma-IGF-1 Laron dwarf mice